Antiphospholipid syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 124: Line 124:
*:* Lupus anticoagulant is also directed against the phospholipid membrane, and requires the cofactor prothrombin.
*:* Lupus anticoagulant is also directed against the phospholipid membrane, and requires the cofactor prothrombin.


==== Catastrophic Antiphospholipid Antibody Syndrome ====
==== Catastrophic Antiphospholipid Antibody Syndrome (CAPS): ====
Classification criteria for CAPS is as follows:
 
{| class="wikitable"
! colspan="4" |Classification criteria for CAPS
|-
| colspan="4" |Criteria
|-
| colspan="4" |
{| class="wikitable"
|1. Evidence of involvement of three or more organs, systems, and/or tissues
|-
|2. Development of manifestations simultaneously or in less than a week
|-
|3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue
|-
|4. Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta2-glycoprotein I antibodies)
|}
|-
|
|
|
|
|}
* A subset of patients with antiphospholipid antibody syndrome develop a catastrophic illness characterized by progressive, severe arterial and venous thrombosis in multiple organs, often leading to death.   
* A subset of patients with antiphospholipid antibody syndrome develop a catastrophic illness characterized by progressive, severe arterial and venous thrombosis in multiple organs, often leading to death.   
* Though specific diagnostic criteria have not been established, some have suggested that criteria include documented thrombosis in 3 or more organs.   
* Though specific diagnostic criteria have not been established, some have suggested that criteria include documented thrombosis in 3 or more organs.   

Revision as of 20:55, 17 April 2018

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome pathophysiology

CDC on Antiphospholipid syndrome pathophysiology

Antiphospholipid syndrome pathophysiology in the news

Blogs on Antiphospholipid syndrome pathophysiology

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

Antiphospholipid syndrome (APS) is an autoimmune disease in which antiphospholipid antibodies (anti-cardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms.

Pathophysiology

The pathogenesis of antiphospholipid syndrome is as follows:

Primary APS

This type of APS has no other associated condition.

Secondary APS

The type of APS which occurs secondary to an underlying disease. The diseases associated with APS are as follows:[1][2][3]

Autoimmune diseases Infections Drugs Malignancy
  • Systemic lupus erythmatosus(SLE)
Bacterial infections:

Viral infections:

Parasitic infections:

Tumors of the following organs can cause APS:

Cancers:

Types of antiphospholipid antibodies

The following antiphospholipid antibodies are found in the plasma of patients:

Antiphospholipid antibodies Percentage
Anticardiolipin antibody 31%
Antilupus antibody 23-47%
Beta-2 glycoprotein 20%

Mechanism of action

The mechanism by which clinical manifestations occur in APS is mainly mediated by the antibodies which is as follows: [7][8][9][10][11][12][13]

Vascular thrombosis

Increased vascular tone:

Another effect of aPL is increased vascular tone which subsequently results in the following manifestations:

Beta2-glycoprotein-I:

These antibodies have the following mechanism of action:

  • They bind negatively charged phospholipids and inhibit contact activation of the clotting cascade and platelet activation.
  • Anticardiolipin antibody
    • The antibody is directed against beta2-glycoprotein-I and cardiolipin, a phospholipid component of cell membranes, also used as an antigen in the assay for syphilis (why syphilis elicits an antibody response to cardiolipin is not clear).
    • Patients with anticardiolipin antibody are more likely to have arterial clots than those with lupus anticoagulant. These patients are also at increased risk for early coronary artery bypass graft (CABG) graft occlusion, premature coronary artery disease (CAD), and valvular heart disease.
  • Lupus Anticoagulant
    • Lupus anticoagulant is a misnomer: it’s actually a pro-coagulant in vivo, and is often seen in patients without lupus. It usually (not always) elevates the lab reading of the partial thromboplastin time (PTT).
    • Lupus anticoagulant is also directed against the phospholipid membrane, and requires the cofactor prothrombin.

Catastrophic Antiphospholipid Antibody Syndrome (CAPS):

Classification criteria for CAPS is as follows:

Classification criteria for CAPS
Criteria
1. Evidence of involvement of three or more organs, systems, and/or tissues
2. Development of manifestations simultaneously or in less than a week
3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue
4. Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta2-glycoprotein I antibodies)
  • A subset of patients with antiphospholipid antibody syndrome develop a catastrophic illness characterized by progressive, severe arterial and venous thrombosis in multiple organs, often leading to death.
  • Though specific diagnostic criteria have not been established, some have suggested that criteria include documented thrombosis in 3 or more organs.
    • Commonly involved organs include the central nervous system (CNS), kidney and distal extremities with acral necrosis. Hypertension is also commonly present, and may be malignant.
    • Histopathology shows evidence of multiple small and/or large vessel occlusions.
  • Frequently no specific etiology is identifiable, and patients present quite suddenly without any obvious precipiting factors.

Genetic association

Antiphospholipid antibody syndrome is associated with the following genetic mutations:

  • Factor V Leiden
  • Prothrombin gene mutation
  • Activated protein C resistance

Gross Pathology Findings

Microscopic Pathology Findings

The histologic findings seen in APS are as follows: Histologic studies of skin or other involved tissues reveal the following:

References

  1. Taraborelli M, Leuenberger L, Lazzaroni MG, Martinazzi N, Zhang W, Franceschini F; et al. (2016). "The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus". Lupus. 25 (12): 1365–8. doi:10.1177/0961203316637431. PMID 26945023.
  2. Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA; et al. (2016). "The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort". Lupus. 25 (7): 719–26. doi:10.1177/0961203315627199. PMID 26821965.
  3. Love PE, Santoro SA (1990). "Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance". Ann Intern Med. 112 (9): 682–98. PMID 2110431.
  4. McNeil HP, Chesterman CN, Krilis SA (1991). "Immunology and clinical importance of antiphospholipid antibodies". Adv Immunol. 49: 193–280. PMID 1853785.
  5. Safa O, Crippa L, Della Valle P, Sabbadini MG, Viganò D'Angelo S, D'Angelo A (1999). "IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome". Haematologica. 84 (9): 829–38. PMID 10477458.
  6. Triplett DA (1998). "Many faces of lupus anticoagulants". Lupus. 7 Suppl 2: S18–22. PMID 9814666.
  7. Bick, RL, et al. Antiphospholipid and thrombosis syndromes. Sem Thromb and Hemostasis 1994;20:3. PMID 8059232
  8. Cervera, R, et al. Clinicopathologic correlations of the antiphospholipid syndrome. Sem Arth and Rheum 1995;24:262. PMID 7740306
  9. Kampe, CE. Clinical syndromes associated with lupus anticoagulants. Sem Thromb and Hemostasis 1994;20:16. PMID 8059230
  10. Asherson, RA. The catastrophic antiphospholipid antibody syndrome. J Rheum 1992:19:508. PMID 1593568
  11. Ruffatti, A, et al. A catastrophic antiphospholipid antibody syndrome: the importance of high levels of warfarin anticoagulation. J Int Med 1994;325:81.PMID8283165
  12. Neuwelt, CM, et al. Catastrophic antiphospholipid syndrome: Response to repeated plasmapheresis. A&R 1997;40:1534. PMID 9259436
  13. Bermas, BL, et al. Prognosis and therapy of antiphospholipid antibody syndrome. UpToDate 1997.

Template:WH Template:WS